As an oral targeted drug, Selpercatinib is easy to use and has high patient compliance. By inhibiting RET kinase activity, Selpercatinib effectively blocks the abnormal growth and spread of diseased cells, bringing long-lasting disease control to patients. So, what are the precautions for the use of Selpercatinib(Retevmo)?

What are the precautions for the use of Selpercatinib (Retevmo)?

Selpercatinib is mainly used to treat diseases with RET gene mutations or fusions. The following is a detailed introduction to the precautions for the use of Selpercatinib:

Doctor's Guidance

Selpercatinib is a prescription drug and must be used under the guidance of a doctor. Patients should fully communicate with their doctors to understand the nature of the drug, the scope of application, the method of medication, and possible adverse reactions.

Regular monitoring

During the use of Selpercatinib, patients should have regular blood tests, liver function monitoring and electrocardiogram to evaluate the efficacy and adverse reactions of the drug.

Drug Interactions

Selpercatinib may interact with certain medications, affecting the drug's efficacy or increasing the risk of adverse effects. Before use, patients should inform their doctor of all medications they are taking, including prescription medications, over-the-counter medications, and supplements.

Selpercatinib is a potent RET kinase inhibitor, but special attention should be paid to the above aspects during use. Patients should be treated individually under the guidance of a physician and followed up regularly to assess the effectiveness of treatment.

Pharmacokinetics of Selpercatinib (Retevmo)

The pharmacokinetic properties of Selpercatinib (Retevmo) are as follows:

Metabolism

Selpercatinib is mainly metabolized by the liver, and the main metabolic pathways include oxidation, hydrolysis and binding reactions. A variety of metabolites may be produced during the metabolism of drugs, and Selpercatinib is mainly metabolized by the CYP3A4 enzyme, and it is necessary to pay attention to the interaction with other drugs that may affect the activity of the CYP3A4 enzyme when using it.

Excretion

Metabolized Selpercatinib and its metabolites are mainly excreted by the kidneys. Patients with renal impairment need to pay attention to monitoring renal function when using it, and adjust the dose according to renal function. Some metabolites may also be excreted in the stool.

Selpercatinib has unique pharmacokinetic properties that allow Selpercatinib to maintain effective drug concentrations in the body, allowing it to exert a sustained therapeutic effect. It is still necessary to pay attention to the differences in pharmacokinetics in special populations and the problem of drug interactions.